Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 25 entries
View as:

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT00513214 Org: User:
Start: 07/31/07 End: 02/28/10 Due: 02/28/11

Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas

Phase: N/A Priority: Normal
NCT ID: NCT00051675 Org: User:
Start: 07/31/02 End: 09/30/03 Due: 09/30/04

Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00998699 Org: User:
Start: 02/28/10 End: 08/31/13 Due: 08/31/14

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01747538 Org: User:
Start: 10/31/12 End: - Due: -

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Phase: N/A Priority: Normal
NCT ID: NCT02318914 Org: User:
Start: 11/30/14 End: 02/29/16 Due: 02/28/17

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

Phase: N/A Priority: Normal
NCT ID: NCT02604485 Org: User:
Start: 10/31/15 End: 01/31/17 Due: 01/31/18

The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease

Phase: N/A Priority: Normal
NCT ID: NCT01950312 Org: User:
Start: 08/31/13 End: 12/31/15 Due: 12/31/16

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Phase: N/A Priority: Normal
NCT ID: NCT01882504 Org: User:
Start: 05/31/13 End: 10/31/15 Due: 10/31/16

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Phase: N/A Priority: Normal
NCT ID: NCT01882491 Org: User:
Start: 05/31/13 End: 02/28/14 Due: 02/28/15

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis

Phase: N/A Priority: Normal
NCT ID: NCT01684345 Org: User:
Start: 08/31/12 End: - Due: -

Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Phase: N/A Priority: Normal
NCT ID: NCT00454155 Org: User:
Start: 02/28/07 End: 06/30/10 Due: 06/30/11

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

Phase: N/A Priority: Normal
NCT ID: NCT02258867 Org: User:
Start: 11/30/14 End: 11/30/15 Due: 11/30/16

Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.

Phase: N/A Priority: Normal
NCT ID: NCT00034203 Org: User:
Start: 04/30/02 End: 08/31/03 Due: 08/31/04

Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT00541983 Org: User:
Start: 09/30/07 End: 02/28/10 Due: 02/28/11

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02772718 Org: User:
Start: 04/30/16 End: 05/31/21 Due: 05/31/22

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Phase: N/A Priority: Normal
NCT ID: NCT02315417 Org: User:
Start: 11/30/14 End: 03/31/16 Due: 03/31/17

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Phase: N/A Priority: Normal
NCT ID: NCT02326740 Org: User:
Start: 12/31/14 End: 03/31/16 Due: 03/31/17

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01066715 Org: User:
Start: 01/31/10 End: 07/31/11 Due: 07/31/12

Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00777816 Org: User:
Start: 02/28/09 End: - Due: -

Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand

Phase: N/A Priority: Normal
NCT ID: NCT02293564 Org: User:
Start: 03/31/13 End: - Due: -

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT01498874 Org: User:
Start: 12/31/11 End: 06/30/13 Due: 06/30/14

Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00051662 Org: User:
Start: - End: 02/29/04 Due: 02/28/05

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

Phase: N/A Priority: Normal
NCT ID: NCT02258854 Org: User:
Start: 03/31/14 End: 12/31/17 Due: 12/31/18

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Phase: N/A Priority: Normal
NCT ID: NCT01683396 Org: User:
Start: 07/31/12 End: 02/28/14 Due: 02/28/15

Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT01144975 Org: User:
Start: 05/31/10 End: 10/31/11 Due: 10/31/12